Inside the GLP-1 Boom: What a Biotech Analyst and PhD/Nutritionist Thinks Mini-deep dive on the fastest growing healthcare opportunity from an investment and health perspective This is for: Science enthusiasts Pharma/biotech consultants, analysts Investors in the life science space Doctors, nutritionists, health coaches, fitness coaches People considering or already on weight loss medication Longevity enthusiasts I help you: Understand what weight loss medications are Get a list of the key obesity players in the pharma/biotech space Understand lifestyle strategies to get the best outcomes out of GLP1s Free Resources included: Obesity development landscape and launch timelines Weight loss data from key drugs in development Comment Health and I will share a US market model template to help you forecast weight loss drug sales yourself See inside for disclosure Intro to Weight Loss Medications (WLMs) Unless you are living under a rock, the words GLP1, Ozempic, Wegovy, Mounjaro, weight-loss medication must not be new to you
Limited data exists for severe hepatic impairment, and both should be used with caution in this population
doi:10.3389/fendo.2023.1215356 Parker CH, Slattery C, Brennan DJ, le Roux CW
What Do Studies Say About GHK-Cu
Patients taking oral semaglutide often experience improvements in key cardiovascular risk factors, including reductions in systolic blood pressure, lower cholesterol levels, and better blood sugar control
Look at the S number on the bottom right of your member ID card
